Disclosed herein are methods for synthesizing fatty olefin metathesis products of high Z-isomeric purity from olefin feedstocks of low Z-isomeric purity. The methods include contacting a contacting an olefin metathesis reaction partner, such as acylated alkenol or an alkenal acetal, with an internal olefin in the presence of a Z-selective metathesis catalyst to form the fatty olefin metathesis product. In various embodiments, the fatty olefin metathesis products are insect pheromones. Pheromone compositions and methods of using them are also described.

Disclosed herein are methods for synthesizing fatty olefin metathesis products of high Z-isomeric purity from olefin feedstocks of low Z-isomeric purity. The methods include contacting a contacting an olefin metathesis reaction partner, such as acylated alkenol or an alkenal acetal, with an internal olefin in the presence of a Z-selective metathesis catalyst to form the fatty olefin metathesis product. In various embodiments, the fatty olefin metathesis products are insect pheromones. Pheromone compositions and methods of using them are also described.

A catalyst has a modified silica support and comprises a modifier metal, zirconium and/or hafnium, and a catalytic metal on the modified support. The catalyst has at least a proportion, typically, at least 25%, of modifier metal present in moieties having a total of up to 2 modifier metal atoms. The moieties may be derived from a monomeric and/or dimeric cation source. A method of production:— provides a silica support with isolated silanol groups with optional treatment to provide isolated silanol groups (—SiOH) at a level of <2.5 groups per nm.sup.2; contacting the optionally treated silica support with a monomeric zirconium or hafnium modifier metal compound to effect adsorption onto the support; optionally calcining the modified support for a time and temperature sufficient to convert the monomeric zirconium or hafnium compound adsorbed on the surface to an oxide or hydroxide of zirconium or hafnium in preparation for catalyst impregnation.

A catalyst has a modified silica support and comprises a modifier metal, zirconium and/or hafnium, and a catalytic metal on the modified support. The catalyst has at least a proportion, typically, at least 25%, of modifier metal present in moieties having a total of up to 2 modifier metal atoms. The moieties may be derived from a monomeric and/or dimeric cation source. A method of production:— provides a silica support with isolated silanol groups with optional treatment to provide isolated silanol groups (—SiOH) at a level of <2.5 groups per nm.sup.2; contacting the optionally treated silica support with a monomeric zirconium or hafnium modifier metal compound to effect adsorption onto the support; optionally calcining the modified support for a time and temperature sufficient to convert the monomeric zirconium or hafnium compound adsorbed on the surface to an oxide or hydroxide of zirconium or hafnium in preparation for catalyst impregnation.

Methods, systems, and computer readable media may be operable to facilitate an anticipation of an execution of a process termination tool. An allocation stall counter may be queried at a certain frequency, and from the query of the allocation stall counter, a number of allocation stall counter increments occurring over a certain duration of time may be determined. If the number of allocation stall counter increments is greater than a threshold, a determination may be made that system memory is running low and that an execution of a process termination tool is imminent. In response to the determination that system memory is running low, a flag indicating that system memory is running low may be set, and one or more programs, in response to reading the flag, may free memory that is not necessary or required for execution.

Methods, systems, and computer readable media may be operable to facilitate an anticipation of an execution of a process termination tool. An allocation stall counter may be queried at a certain frequency, and from the query of the allocation stall counter, a number of allocation stall counter increments occurring over a certain duration of time may be determined. If the number of allocation stall counter increments is greater than a threshold, a determination may be made that system memory is running low and that an execution of a process termination tool is imminent. In response to the determination that system memory is running low, a flag indicating that system memory is running low may be set, and one or more programs, in response to reading the flag, may free memory that is not necessary or required for execution.

The present invention reports the obtaining of carbonyl compounds and derivatives, through syntheses with high yield and purity, providing anti-humoral active principles with selective antiproliferative properties and anti-metastatic activity.

The present invention refers to the development of new polyfunctional push-pull butadienes and their O and C-prenylated, benzoylated and iodide derivatives, with high electronic conjugation in the lateral chain. These compounds exhibit high anti-tumor selectivity, causing cell death by apoptosis, also show anti-metastatic and non-mutagenic properties in the experimental studies performed.

The present invention reports the obtaining of carbonyl compounds and derivatives, through syntheses with high yield and purity, providing anti-humoral active principles with selective antiproliferative properties and anti-metastatic activity.

The present invention refers to the development of new polyfunctional push-pull butadienes and their O and C-prenylated, benzoylated and iodide derivatives, with high electronic conjugation in the lateral chain. These compounds exhibit high anti-tumor selectivity, causing cell death by apoptosis, also show anti-metastatic and non-mutagenic properties in the experimental studies performed.

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.